Survival of patients with carcinoma in situ of the urinary bladder

Cancer

Volumn 85, Issue 11, 1999, Pages 2469-2474

  Cheng, Liang ^a,c   Cheville, John C ^b   Neumann, Roxann M ^b   Leibovich, Bradley C ^b   Egan, Kathleen S ^b   Spotts, Bruce E ^b   Bostwick, David G ^b  

^a INDIANA UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma in situ; Cystectomy; Precursor; Progression; Survival; Treatments; Urinary bladder

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0033152559     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U     Document Type: Article

References (31)

1. Landis S, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Prout GR, Griffin PP, Daly JJ, Heney NM. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer 1983;52:524-32.
3. Althausen AF, Prout GR, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-80.
4. Kakizoe T, Matumoto K, Nishio Y, Ohtani M, Kishi K. Significance of carcinoma in situ and dysplasia in association with bladder cancer. J Urol 1985;133:395-8.
5. Orozco RE, Martin AA, Murphy WM. Carcinoma in situ of the urinary bladder: clues to host involvement in human carcinogenesis. Cancer 1994;74:115-22.
6. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995:153:564-72.
7. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19: 499-508.
8. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urologic Pathology consensus, classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22: 1435-48.
9. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al., editors. American Joint Committee on Cancer cancer staging manual. 5th edition. Philadelphia: Raven-Lippincott, 1997.
10. Weinstein RS, Miller AW, Pauli BU. Carcinoma in situ: comments on the pathobiology of a paradox. Urol Clin North Am 1980;7:523-31.
11. Melamed MR, Voutsa NG, Grabstald H. Natural history and clinical behavior of in situ carcinoma of the human urinary bladder. Cancer 1964;17:1533-45.
12. Koss LG, Tiamson EM, Robins MA. Mapping cancerous and precancerous changes. A study of the urothelium in 10 surgically removed bladders. JAMA 1974;227:281-6.
13. Koss LG, Melamed MR, Kelly RE. Further cytologic and histologic studies of bladder lesions in workers exposed to para-aminodiphenyl: progress report. J Natl Cancer Inst 1969;43:233-43.
14. Riddle PR, Chisholm GD, Trott PA, Pugh RCB. Flat carcinoma in situ of bladder. Br J Urol 1976;47:829-33.
15. Utz DC, Hanash KA, Farrow GM. The plight of the patient with carcinoma of the bladder. J Urol 1970;103:160-4.
16. Utz DC, Farrow GM. Carcinoma in situ of the urinary tract. Urol Clin North Am 1984;11:735-40.
17. Farrow GM, Utz DC, Rife CC, Greene LF. Clinical observation on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 1977;37:2794-8.
18. Utz DC, Zincke H. The masquerade of bladder cancer in situ as interstitial cystitis. J Urol 1974;111:160-1.
19. Utz DC, Farrow GM, Rife CC, Segura JW, Zincke H. Carcinoma in situ of the bladder. Cancer 1980;45:1842-8.
20. Zincke H, Utz DC, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology 1985;26(Suppl):39-46.
21. Farrow GM, Utz DC, Rife CC. Morphological and clinical observation of patients with early bladder cancer treated with total cystectomy. Cancer Res 1976;36:2495-501.
22. Stanisic TH, Donovan JM, Lebouton J, Graham AR. 5 year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management. J Urol 1987;138:1158-61.
23. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-7.
24. Herr HW, Laudone UP, Badalament RA, Oettgen HF, Freedman BD, Melamed MR, et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988;6:1450-5.
25. Lamm DL, Blumensten BA, Crawford ED, Montie JE, Scardino P, Grosman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med 1991;325:1205-9.
26. Lamm DL. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology 1995;9:947-52.
27. Herr HW, Fradet Y, Klein FA. Summary of effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Semin Urol Oncol 1997;15:80-5.
28. Hofstadter F, Delgado R, Jakse G, Judmaier W. Urothelial dysplasia and carcinoma in situ of the bladder. Cancer 1986; 57:356-61.
29. Norming U, Tribukait B, Gustafson H, Nyman CR, Wang N, Wijkstrom H. Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions. J Urol 1992;147:11-5.
30. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang Z, Sheinfeld J, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388-92.
31. WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9.